Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more
Market Cap & Net Worth: Amgen Inc (AMGN)
Amgen Inc (NASDAQ:AMGN) has a market capitalization of $194.65 Billion ($194.65 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #74 globally and #61 in its home market, demonstrating a -4.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amgen Inc's stock price $361.13 by its total outstanding shares 539000000 (539.00 Million).
Amgen Inc Market Cap History: 2015 to 2026
Amgen Inc's market capitalization history from 2015 to 2026. Data shows growth from $67.11 Billion to $194.65 Billion (11.35% CAGR).
Index Memberships
Amgen Inc is a constituent of 10 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$879.22 Billion | 22.08% | #1 of 30 |
|
DJC: Dow Jones-UBS Commodity Index
DJC
|
$21.31 Trillion | 2.88% | #19 of 65 |
|
Dow Jones Industrial Average
DJI
|
$19.60 Trillion | 4.37% | #19 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 16.88% | #2 of 39 |
|
S&P 500 Index
GSPC
|
$53.17 Trillion | 0.34% | #43 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 8.67% | #2 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.58% | #21 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 12.61% | #2 of 263 |
|
Nasdaq 100
NDX
|
$28.06 Trillion | 0.69% | #20 of 101 |
|
S&P 100
OEX
|
$37.26 Trillion | 0.48% | #39 of 101 |
Weight: Amgen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amgen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amgen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.80x
Amgen Inc's market cap is 4.80 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
22.88x
Amgen Inc's market cap is 22.88 times its annual earnings
11.18x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $62.03 Billion | $22.99 Billion | $7.72 Billion | 2.70x | 8.03x |
| 2017 | $75.85 Billion | $22.85 Billion | $1.98 Billion | 3.32x | 38.33x |
| 2018 | $87.40 Billion | $23.75 Billion | $8.39 Billion | 3.68x | 10.41x |
| 2019 | $111.53 Billion | $23.36 Billion | $7.84 Billion | 4.77x | 14.22x |
| 2020 | $109.31 Billion | $25.42 Billion | $7.26 Billion | 4.30x | 15.05x |
| 2021 | $110.28 Billion | $25.98 Billion | $5.89 Billion | 4.24x | 18.71x |
| 2022 | $132.81 Billion | $26.32 Billion | $6.55 Billion | 5.05x | 20.27x |
| 2023 | $150.69 Billion | $28.19 Billion | $6.72 Billion | 5.35x | 22.43x |
| 2024 | $140.48 Billion | $33.42 Billion | $4.09 Billion | 4.20x | 34.35x |
| 2025 | $176.42 Billion | $36.74 Billion | $7.71 Billion | 4.80x | 22.88x |
Competitor Companies of AMGN by Market Capitalization
Companies near Amgen Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Amgen Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $830.88 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #17 globally with a market cap of $572.79 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #28 globally with a market cap of $387.90 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $295.24 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $830.88 Billion | $930.35 |
| #17 | Johnson & Johnson | NYSE:JNJ | $572.79 Billion | $238.11 |
| #28 | AbbVie Inc | NYSE:ABBV | $387.90 Billion | $219.76 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $295.24 Billion | $191.29 |
Amgen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Amgen Inc's market cap moved from $67.11 Billion to $ 194.65 Billion, with a yearly change of 11.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $194.65 Billion | +10.33% |
| 2025 | $176.42 Billion | +25.58% |
| 2024 | $140.48 Billion | -6.77% |
| 2023 | $150.69 Billion | +13.46% |
| 2022 | $132.81 Billion | +20.43% |
| 2021 | $110.28 Billion | +0.89% |
| 2020 | $109.31 Billion | -1.99% |
| 2019 | $111.53 Billion | +27.60% |
| 2018 | $87.40 Billion | +15.23% |
| 2017 | $75.85 Billion | +22.27% |
| 2016 | $62.03 Billion | -7.57% |
| 2015 | $67.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Amgen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $194.65 Billion USD |
| MoneyControl | $194.65 Billion USD |
| MarketWatch | $194.65 Billion USD |
| marketcap.company | $194.65 Billion USD |
| Reuters | $194.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.